Exiqon A.S.

Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence.
Cancer Weekly; 12/8/2009; 965 words; Exiqon A/S (NASDAQ OMX Copenhagen...through the incorporation of Exiqon's proprietary LNA™...and implementation. That's what these microRNA Centers...institution to be inducted as an Exiqon microRNA Center of Excellence...

News and FDA Updates for Clarient (Nasdaq:CLRT), WuXi (NYSE:WX), Exiqon A/S (NASDAQ:OMX).
M2 Presswire; 12/1/2009; 1035 words; ...Nasdaq:CLRT), WuXi (NYSE:WX), Exiqon A/S (NASDAQ:OMX)(C)1994-2009...portal which covers Wall Street's biomedical sector and delivers financial...consecutive year. On 30/11/09, Exiqon A/S (NASDAQ:OMX) announced the Harvard...

Research and Markets Adds Report: Delivering RNAi-Based Therapeutics & Diagnostics: Challenges & Opportunities.
Health & Beauty Close-Up; 11/4/2009; 812 words; ...Technologies - Silence Therapeutics - Siranoamics, - siRNAsense A/S - Sylentis Pharmaceuticals - Tacere Therapeutics - Targeted...Takeda. RNAi diagnostic companies: - Asuragen Diagnostics - Exiqon Diagnostics - Rosetta Genomics Report information: http...

Other News To Note.
BIOWORLD Today; 11/4/2009; 1668 words; ...appear to contribute to the vaccine's immunogenicity. Bioenvision Inc...right of supply from the Danish company Exiqon A/S to incorporate Locked Nucleic Acid technology into certain of DNAPrint's pharmacogenomics and forensics tests...

Santaris Signs $200M LNA Oncology Pact With Enzon.
BIOWORLD Today; 11/3/2009; 1204 words; ...in 2003 of Vedbaek, Denmark-based Cureon A/S and Copenhagen-based Pantheco A/S, has sole rights to therapeutic applications of LNA. Vedbaek-based Exiqon A/S, the original parent of Cureon, holds rights...